NeuroMetrix (NURO) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free NURO Stock Alerts $3.83 +0.03 (+0.79%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comMay 28, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Shares Pass Above 200-Day Moving Average of $3.71May 15, 2024 | globenewswire.comNeuroMetrix Reports Q1 2024 Business HighlightsApril 24, 2024 | finance.yahoo.comNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearApril 20, 2024 | investing.comNeuroMetrix appoints new board director, ends ATM facilityApril 19, 2024 | markets.businessinsider.comNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsApril 19, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 19, 2024 | globenewswire.comNeuroMetrix Announces Steps Taken to Enhance Shareholder ValueMarch 14, 2024 | globenewswire.comNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyMarch 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaMarch 13, 2024 | globenewswire.comNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaMarch 8, 2024 | finanznachrichten.deRS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.March 8, 2024 | finance.yahoo.comRS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.February 25, 2024 | au.lifestyle.yahoo.comGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesFebruary 24, 2024 | finance.yahoo.comNeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)February 23, 2024 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | globenewswire.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 15, 2024 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 15, 2024 | globenewswire.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueFebruary 13, 2024 | markets.businessinsider.comNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsFebruary 13, 2024 | finance.yahoo.comNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueJanuary 8, 2024 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024December 12, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)December 12, 2023 | finance.yahoo.comNeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)December 5, 2023 | finance.yahoo.comNeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)November 30, 2023 | msn.comOPEN, AMPE and NURO are among pre market gainersNovember 22, 2023 | marketbeat.comTrading was temporarily halted for "NURO" at 07:11 PM with a stated reason of "News pending."November 20, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces One-for-Eight Reverse Stock SplitNovember 20, 2023 | finance.yahoo.comNeuroMetrix Announces One-for-Eight Reverse Stock SplitOctober 30, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023October 28, 2023 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call TranscriptOctober 26, 2023 | msn.comNeuroMetrix reports Q3 resultsOctober 26, 2023 | finance.yahoo.comNeuroMetrix Reports Q3 2023 Business HighlightsOctober 23, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallOctober 2, 2023 | finance.yahoo.comNeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaSeptember 28, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023August 30, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023August 28, 2023 | finance.yahoo.comIs NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapJuly 27, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business HighlightsJuly 27, 2023 | finance.yahoo.comNeuroMetrix Reports Q2 2023 Business HighlightsJuly 20, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallJuly 11, 2023 | finance.yahoo.comNeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaJune 28, 2023 | finance.yahoo.comRecent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsJune 7, 2023 | finance.yahoo.comDiabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyMay 31, 2023 | finance.yahoo.comQuell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)May 16, 2023 | bizjournals.comAutonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&DMay 3, 2023 | finance.yahoo.comNeuroMetrix Reports Q1 2023 Financial Results Get NeuroMetrix News Delivered to You Automatically Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. NURO Media Mentions By Week NURO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NURO News Sentiment▼0.850.76▲Average Medical News Sentiment NURO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NURO Articles This Week▼30▲NURO Articles Average Week Get NeuroMetrix News Delivered to You Automatically Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NeuroOne Medical Technologies News Today Femasys News Today Spectral AI News Today Retractable Technologies News Today SeaStar Medical News Today Inspira Technologies Oxy B.H.N. News Today T2 Biosystems News Today Nephros News Today PolyPid News Today Lyra Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NURO) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
